hbp_logo-BIG-P

Cancer

A central goal of cancer therapy is to selectively target the tumor and minimize toxicity for healthy tissue. Hamlet Biopharma is developing new therapeutic solutions for targeting and killing tumor cells with greater precision. Alpha1H is one of Hamlet Biopharma’s main drug candidates. Alpha1H is a synthetically manufactured peptide in complex with oleic acid and an efficient anti-tumor drug candidate for the treatment of bladder cancer and brain tumors.

Bladder cancer

In patients with bladder cancer, Alpha1H has been shown to target the tumors, without harming healthy tissues in treated patients. Bladder cancer is common, treatment is costly and often inefficient and there is a great need for new therapies.

Read More

Brain Tumor

In patients with bladder cancer, Alpha1H has been shown to target the tumors, without harming healthy tissues in treated patients. Bladder cancer is common, treatment is costly and often inefficient and there is a great need for new therapies.

Read More

Alpha1H

In patients with bladder cancer, Alpha1H has been shown to target the tumors, without harming healthy tissues in treated patients. Bladder cancer is common, treatment is costly and often inefficient and there is a great need for new therapies.

Read More

Mechanism of cell death

In patients with bladder cancer, Alpha1H has been shown to target the tumors, without harming healthy tissues in treated patients. Bladder cancer is common, treatment is costly and often inefficient and there is a great need for new therapies.

Read More
hbp_logo-BIG-P
An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.
Hamlet BioPharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958
Subscribe to receive
Pressreleases and Newsletters
© 2025
Hamlet BioPharma.